Association between brown adipose tissue activity and clinical outcomes in melanoma: a retrospective PET/CT analysis [0.03%]
棕色脂肪组织活性与黑色素瘤临床转归的关系：回顾性PET/CT分析
P Toivanen,P Ketola,T Vahlberg et al.
P Toivanen et al.
Background: Brown adipose tissue (BAT) activity has been suggested to play a role in cancer progression. Previous studies have shown that BAT activity is higher in patients with cancer, and that BAT volume is a predictor ...
Th17-mediated antitumor immunity in patient-derived organoid and autologous immune cell cocultures predicts response to immunotherapy in head and neck cancer [0.03%]
来自患者衍生的类器官和同种免疫细胞共培养物的Th17介导的抗肿瘤免疫预测头颈部癌症对免疫疗法的反应
P Meißner,P Kaps,T Momper et al.
P Meißner et al.
Background: Immune checkpoint inhibitor (ICI) therapy improves survival in head and neck squamous cell carcinoma (HNSCC), yet only some patients benefit, highlighting the need for early identification of responders and fu...
K M Yap,P K Darcy,P A Beavis et al.
K M Yap et al.
Combining circulating inflammatory proteins and thymidine kinase activity to predict survival in melanoma patients receiving immune checkpoint inhibitors [0.03%]
联合循环炎症蛋白和胸苷激酶活性预测接受免疫检查点抑制剂黑色素瘤患者的生存期
S Egyhazi Brage,F Costa Svedman,M Bergqvist et al.
S Egyhazi Brage et al.
Background: Inflammatory plasma proteins have been associated with poorer clinical outcomes in melanoma patients treated with immune checkpoint inhibitors (ICIs). Furthermore, the plasma levels of thymidine kinase activit...
Fresh-blood immune profiling of immune-related adverse events in real-world patients identifies organ-specific and steroid responsiveness signatures [0.03%]
基于真实世界患者的新鲜血液免疫特征分析鉴定出与免疫相关不良事件的器官特异性和激素反应性标志物
M Velasco Santiago,R S Jurlander,B Albieri et al.
M Velasco Santiago et al.
Background: Immune checkpoint inhibition (ICI) provides durable benefit across several cancers but carries a substantial risk of immune-related adverse events (irAEs). Management relies primarily on corticosteroids, yet r...
The effect of neoadjuvant radiotherapy on immune cell infiltrates in myxofibrosarcoma [0.03%]
术前放疗对黏液型纤维肉瘤浸润性免疫细胞的影响
M J L Nederkoorn,U E Flucke,M H S Hillebrandt-Roeffen et al.
M J L Nederkoorn et al.
Background: Myxofibrosarcoma (MFS) is a subtype of soft-tissue sarcoma for which local treatment includes neoadjuvant radiotherapy (nRT) followed by surgery. The impact of nRT on the MFS tumor immune microenvironment rema...
Safety of intratumoral immunostimulatory LOAd703 gene therapy combined with chemotherapy in patients with advanced cancer [0.03%]
联合使用化疗的瘤内免疫刺激LOAd703基因治疗在晚期癌症患者中的安全性研究
A Hahn,S Irenaeus,L C Sandin et al.
A Hahn et al.
Background: LOAd703 is a tumor microenvironment (TME) gene-engineering adenovirus encoding the immunostimulatory transgenes trimerized membrane-bound CD40 ligand (CD40L) and 4-1BB ligand (4-1BBL). Upon administration in t...
Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy [0.03%]
基于瞬时mRNA的CD117 CAR-T细胞有效靶向急性髓系白血病（体外模型）作为预处理策略的潜在应用
T Inthanachai,C Sittplangkoon,H Tashiro et al.
T Inthanachai et al.
Background: Acute myeloid leukemia (AML) is a high-risk malignancy, particularly in patients with primary induction failure or relapsed/refractory disease. CD117 (c-Kit), expressed on both leukemic blasts and normal hemat...
Redirecting engineered immune cells using G protein-coupled receptors in cancer therapy [0.03%]
基于G蛋白偶联受体的工程化免疫细胞重定向在癌症治疗中的应用
W den Hartog,J Harwood,S Kobold
W den Hartog
Chimeric antigen receptor (CAR) cellular therapy, particularly CAR-T cells, has revolutionized the treatment of hematologic malignancies. However, these therapies show limited efficacy against solid tumors, in part due to the inefficient tr...
Safety and efficacy of immune checkpoint inhibitors in patients with melanoma and pre-existing autoimmune conditions: a systematic review and meta-analysis [0.03%]
免疫检查点抑制剂治疗黑素瘤合并自身免疫性疾病的疗效和安全性：系统评价和Meta分析
S Haider,M Hong,J Descallar et al.
S Haider et al.
Background: Melanoma patients with pre-existing autoimmune diseases (AIDs) have been excluded from clinical trials of immune checkpoint inhibitors (ICIs), due to a risk of flare and immune-related adverse effects (irAEs)....